The 67th Annual Meeting of the American Society of Hematology (ASH) was held in Orlando from December 6 to 9, 2025, bringing together the latest global advances in hematologic research and clinical practice. At this year’s meeting, four studies led by Prof. Yajing Zhang from Beijing Gobroad Boren Hospital were accepted, including one oral presentation.

In recent years, with the rapid development of precision genomics, hereditary predisposition genes have gained increasing attention for their clinical value in the diagnosis and treatment of hematologic malignancies. At the 67th Annual Meeting of the American Society of Hematology (ASH), a study led by Professor Li Zhihui from Beijing Gaobo Boren Hospital was selected for oral presentation, systematically evaluating the impact of hereditary predisposition genes on outcomes of allogeneic hematopoietic stem cell transplantation (allo-HSCT) and donor selection. Hematology Frontier invited Professor Li for an in-depth interpretation of this study and its implications for clinical practice.

At the annual meeting of the American Society of Hematology (ASH), research in FLT3-ITD acute myeloid leukemia (AML) delivered important advances for clinical practice. Notably, the latest findings from the QUIWI study series further revealed that, among FLT3-ITD–negative patients, FLT3 ligand (FL) levels and microclonal status can help identify prognostic heterogeneity, offering a new paradigm for dynamic monitoring and risk-adapted intervention. On site, Oncology Frontier · Hematology Frontier invited Professor Wang Jianxiang from the Institute of Hematology, Chinese Academy of Medical Sciences, to discuss key advances, including the prognostic value of FLT3 ligand, the clinical relevance of microclonal detection, and the therapeutic potential of quizartinib, with the aim of building a comprehensive FLT3-marker–based management framework to advance AML care toward greater precision and dynamism.

At this year’s American Society of Hematology (ASH) Annual Meeting, advances in FLT3-ITD acute myeloid leukemia (AML) delivered important clinical insights. From evolving treatment paradigms to optimized maintenance strategies and breakthroughs in targeted therapy, these studies consistently centered on precision medicine, driving care toward greater efficiency and individualization. On site at ASH, Hematology Frontier invited Professor Jun Ma from the Harbin Institute of Hematology and Oncology to interpret key developments in dynamic management, maintenance therapy, and targeted drug application in FLT3-ITD AML, with the aim of informing clinical decision-making.

The 67th American Society of Hematology (ASH) Annual Meeting will be held in Orlando, Florida, USA, from December 6 to 9, 2025. Three studies from the Department of Hematology of…

From December 6–9, 2025, the 67th American Society of Hematology (ASH) Annual Meeting was held in Orlando, bringing together hematology experts worldwide to share cutting-edge research and major clinical breakthroughs.…

At present, the treatment of myelofibrosis (MF) continues to face significant challenges. A proportion of patients are intolerant of or develop resistance to existing JAK inhibitors, leaving limited subsequent therapeutic…

For patients with relapsed/refractory (R/R) T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LBL), current treatment options remain limited and outcomes are unsatisfactory, posing major clinical challenges. At the Annual Meeting of the…

The 67th Annual Meeting of the American Society of Hematology (ASH) was held in Orlando from December 6 to 9, 2025. As the world’s largest and most influential hematology conference,…